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Abstract
Introduction: We present a case of Mikulicz’s Disease with hypophysitis. This is a rare clinical association as part of the group of IgG4-
related diseases, a group of disorders which can have multiorgan involvement.
Methods: A 55-year-old male patient was diagnosed with Mikulicz’s disease. He was treated with oral steroids for six months with 
complete resolution. After two years the patient presented with fatigue, generalised weakness, and weight loss of 11 kg over six months.
On evaluation he was found to have panhypopituitarism. MRI pituitary revealed homogeneously enlarged, well enhancing pituitary with 
thickening of the stalk. Serum IgG4 levels were significantly elevated. The patient was treated with methyl prednisolone pulse therapy 
followed by oral steroids for three months. He developed diabetes insipidus after starting steroid therapy. There was a significant resolu-
tion in the enlargement of the pituitary and stalk thickening at three months.
Results: The clinical, biochemical, and radiological findings of hypophysitis associated with Mikulicz’s disease are presented with a brief 
review of literature.
Conclusions: IgG4-related diseases are rare and have recently been recognised as a cause of hypophysitis. They can have multiorgan 
involvement. A high index of suspicion is required for clinching this rare diagnosis, which can be confirmed by measurement of serum 
levels of IgG4. Steroid therapy can reverse the inflammatory changes in IgG4 hypophysitis. (Endokrynol Pol 2016; 67 (6): 622–626)
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Streszczenie
Wstęp: W pracy przedstawiono przypadek choroby Mikulicza-Radeckiego z zapaleniem przysadki. Jest to rzadko występujące połączenie 
zaburzeń należących do grupy chorób związanych z IgG4, które mogą obejmować wiele narządów.
Metody: U mężczyzny w wieku 55 lat rozpoznano chorobę Mikulicza-Radeckiego. Stosowano doustne steroidy przez 6 miesięcy, uzysku-
jąc całkowite ustąpienie choroby. Po 2 latach chory zaczął odczuwać zmęczenie i ogólne osłabienie, a ponadto w ciągu 6 miesięcy schudł 
11 kg. Badanie wykazało wielohormonalną niedoczynność przysadki. Badanie rezonansu magnetycznego przysadki uwidoczniło rów-
nomiernie powiększoną, ulegającą wzmocnieniu po podaniu kontrastu, z pogrubioną szypułą. Stężenie IgG4 w surowicy było istotnie 
podwyższone. U pacjenta zastosowano najpierw terapię pulsacyjną metylprednizolonem, a następnie 3-miesięczne leczenie steroidami 
podawanymi doustnie. Po rozpoczęciu leczenia steroidami u chorego rozwinęła się moczówka prosta. Po 3 miesiącach nastąpiło istotne 
zmniejszenie powiększonej przysadki i pogrubionej szypuły.
Wyniki: Przedstawiono kliniczne, biochemiczne i radiologiczne objawy niedoczynności przysadki związanej z chorobą Mikulicza-Ra-
deckiego oraz krótki przegląd literatury.
Wnioski: Choroby związane z IgG4 występują rzadko. W ostatnim czasie wykazano, że mogą powodują one niedoczynność przysadki. 
Mogą one obejmować wiele narządów. Rozpoznanie tej rzadkiej choroby można potwierdzić, oznaczając stężenie IgG4 w surowicy. 
Można potwierdzić diagnozę, mierząc stężenie IgG4 w surowicy. Leczenie steroidami może spowodować ustąpienie zmian zapalnych 
z niedoczynności przysadki związanej z IgG4. (Endokrynol Pol 2016; 67 (6): 622–626)
Słowa kluczowe: IgG4; niedoczynność przysadki; choroba Mikulicza-Radeckiego
Introduction
Immunoglobulin G4 (IgG4)-related diseases or IgG4-
positive multiorgan lymphoproliferative syndrome 
is characterised by dense infiltration of IgG4-positive 
plasma cells (> 50% of infiltrated IgG-positive cells) into 
multiple organs or tissues in association with increased 
serum levels of IgG4 (> 135 mg/dL) [1–2].
The clinical spectrum extends from Mikulicz’s 
disease (MD) to autoimmune pancreatitis and hypo-
physitis. 
Mikulicz’s disease is an autoimmune condition 
characterised by symmetrical and persistently en-
larged lacrimal, salivary, and submandibular glands. It 
was considered as a subtype of Sjögren syndrome for 
a long time, but negative anti-Ro and La antibodies, 
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high serum levels of IgG4, and an infiltration of IgG4-
positive cells within the salivary gland distinguish it 
from Sjögren syndrome.
Herein we report a case of a 55-year-old man with 
MD, presenting with hypophysitis two years later.
Case report
A 55-year-old man without any previous medical dis-
orders developed dry mouth, dry eyes, and bilateral 
submandibular and parotid gland swelling in 2012. 
He was evaluated for Sjögren’s syndrome. His serum 
anti-Ro and -La antibodies were negative. The diagnosis 
of Mikulicz’s disease was considered by exclusion and 
he was started on oral prednisolone 60 mg/day, which 
was gradually tapered over a period of six months. 
The patient had complete resolution of the parotid, 
and the submandibular swellings and dryness of the 
eyes improved.
He was asymptomatic for the next two years, after 
which he presented again with generalised weakness, 
malaise, fatigue, and weight loss of approximately 11 kg 
over six months. His vitals were stable and the systemic 
examination was unremarkable.
His routine investigations (haemogram, renal func-
tion tests, electrolytes, liver function tests, calcium 
profile) were normal. On hormonal evaluation, he was 
found to have secondary hypothyroidism, hypocorti-
solism, and hypogonadism suggestive of panhypopi-
tuitarism. (Table I).
Magnetic Resonance Imaging (MRI) of the pituitary 
showed a diffuse mass lesion of size 14 × 13 × 13 mm 
involving the whole of the pituitary. The pituitary stalk 
was markedly thickened (8 × 9 mm). There was intense 
enhancement with gadolinium (Fig. 1). The posterior 
pituitary bright spot was absent. These findings were 
consistent with lymphocytic hypophysitis.
He was evaluated to rule out other causes of hypo-
physitis (Table II). His serum angiotensin-converting 
enzyme, alpha-fetoprotein, carcinoembryonic antigen, 
and anti-neutrophilic cytoplasmic antibodies were 
negative ruling out most of the other aetiologies. CT 
scan of the chest and abdomen did not show any evi-
dence of tuberculosis or other chronic granulomatous 
lesions. His serum IgG4 levels were 800 mg/dL (3– 
–200 mg/dL), suggesting IgG4-related disease involving 
the pituitary gland. 
Injection methyl prednisolone 1 g IV OD was 
given for three days followed by oral prednisolone 60 
mg/day, which was gradually tapered over the next 
three months. (3) His clinical symptoms, plasma glu-
cose, and serum electrolytes were closely monitored. 
He developed polyuria and polydipsia after initiation 
of steroid therapy. Plasma and urine osmolality were 
suggestive of central diabetes insipidus (Table I). 
His serum Anti-Diuretic Hormone (ADH) was not 
estimated. He was started on L-Thyroxin 100 ugms/ 
/day, injection of testosterone 250 mg intramuscular 
every month, and tablet desmopressin 0.1 mg every 
eight hours. 
Table I. Hormonal profile
Tabela I. Profil hormonalny
Investigation Before Treatment After Treatment at 3 Months
Free T4 (0.8–1.8 ng/dL) 0.39 0.928 
Thyroid Stimulating Hormone (0.35–5.5 uIU/mL) 0.083 3.28 
Prolactin (5–25 ng/mL) 49.04 14.97 
Cortisol (5–25 ugm/dL) 0.77 1.2
ACTH ( 5–20 pg/mL) 12.3 –*
Follicle Stimulation Hormone (2.5 –10 mIU/mL) 0.8 –*
Luteinizing Hormone (2.5–10 mIU/mL) 0.51 –*
Testosterone (4–11 ng/mL) 0.03 3.35 
IGF 1(81–238 ng/mL) 32 –*
Serum IgG4 (3–200 mg/dL) 800 402 
Fasting Plasma Glucose (60–100 mg/dL) 93 86
Serum Osmolality (275–295 mOsm/Kg) 304 294
Urine Osmolality (300–900 mOsm/Kg) 98 562
*Not Repeated
Hormonal evaluation was done 3 months after therapy. He was on thyroxine 100 ugms/day, prednisolone 5 mg/day, T. desmopressin 0.1 mg TDS, and injection 
testosterone enanthate 250 mg intramuscular (3 weeks after the dose). Prednisolone was omitted 24 hours before evaluation.
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At three months, the pituitary imaging showed a 
dramatic reduction in the pituitary swelling. The gland 
measured 10 × 8.6 × 12.7 mm with a stalk of 5.6 × 3.9 
mm. The posterior pituitary bright spot was absent 
(Fig. 1)
A reduction of the serum levels of IgG4 was noted 
(Table I). On hormonal evaluation, his pituitary func-
tions showed no recovery, and currently he is ad-
equately supplemented with thyroxin, prednisolone, 
testosterone, and desmopressin. 
Discussion
We report an extremely rare case of a recently recog-
nised entity, IgG4-related immune hypophysitis with 
panhypopituitarism complicating Mikulicz’s disease. 
To our knowledge, there have been only 29 such cases 
reported so far [4]. The first case of IgG4-related hy-
pophysitis was reported in Japan in the year 2000 [5].
Table II. Differential diagnosis
Tabela II. Rozpoznanie różnicowe
Lymphocytic Hypophysitis
Sarcoidosis
Tuberculosis
Wegener’s Granulomatosis
Germinoma
Pituitary Adenoma
Langerhans Cell Histiocytosis
Figure 1. Upper panel MRI pituitary shows a diffuse mass lesion of size 14 × 13 × 13 mm involving whole of the pituitary. Upper 
arrow shows the pituitary stalk which was markedly thickened (8 × 9 mm). Lower arrow shows the pituitary. Lower panel — Resolution 
of the changes after steroid therapy
Rycina 1. Górny panel  rezonansu magnetycznego przysadki mózgowej przedstawia rozległe zmiany o rozmiarach 14 × 13 × 13 mm 
zajmujące całą jej powierzchnię. Górna strzałka pokazuje znacząco pogrubiony lejek (8 × 9 mm), zaś dolna przysadkę mózgową. Dolny 
panel przedstawia rozwój zmian po terapii steroidowej 
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Table III. Criteria to diagnose IgG4-related hypophysitis [9]
Tabela III. Kryteria diagnostyczne niedoczynności przysadki związanej z IgG4 [9]
Criteria
1 Pituitary histopathology mononuclear infiltration of the pituitary gland, rich in lymphocytes and plasma cells, with more  
than 10 lgG4-positive cells per high-power field
2 Pituitary MRI: Sellar mass and/or thickened pituitary stalk
3 Biopsy-proven involvement in other organs: Association with lgG4-positive lesions in other organs
4 Serology: Increased serum lgG4 (> 140 mg/dL)
5 Response to glucocorticoids: Shrinkage of the pituitary mass and symptom improvement with steroids
Diagnosis of lgG4-related hypophysitis is established when any of the following is fulfilled:
Criterion 1 OR Criteria 2 and 3 OR Criteria 2, 4, and 5
The disease usually affects middle-aged or elderly 
males. The male-to-female ratio is 2.9:1 [6]. Serum IgG4 
measured before giving steroids is much higher than 
that following steroids, as shown by Caputo et al. [7].
The spectrum of IgG4-related disorders is wide. 
It can manifest as Mikulicz’s disease, autoimmune 
pancreatitis, interstitial pneumonitis, retroperitoneal 
fibrosis, interstitial nephritis, pachymeningitis, and as 
inflammatory pseudotumours involving the orbits and 
lungs [1, 2]. These manifestations can occur before hy-
pophysitis. Multiorgan involvement is a feature noted 
throughout the clinical course of IgG4-related diseases.
A dense infiltration of IgG4-positive plasma cells in 
various affected organs is a characteristic finding. The 
exact trigger for IgG4 elevation has not been established. 
Conflicting reports have implicated Th1 cells and Th2 
cells in disease pathophysiology [8]. Within the organs, 
increased CD4-positive T cells lead to activation of in-
nate immune cells, which secrete cytokines and inter-
leukins. This perpetuates the inflammatory response 
and leads to fibrosis.
In the review by Bando et al. [4] only 14% of the 
patients solely exhibited hypophysitis, which was 
diagnosed by histopathology. In 2011 Leporati et al. 
[9] suggested five criteria to diagnose IgG4-related 
hypophysitis (Table III).
Based on criteria 2, 4, and 5 we established the diag-
nosis of IgG4-related hypophysitis in our patient. The 
MRI findings in most of the patients with IgG4-related 
hypophysitis are similar to those observed with other 
causes of hypophysitis. According to previous case 
reports, imaging in IgG4-related hypophysitis may 
present as a thickening and mass of pituitary stalk or 
pituitary gland [10–12].
Hypopituitarism is a well-known result of hypo-
physitis; however, Hattori et al. have reported a case 
with all hormonal axes preserved [13].
Almost all cases of IgG4-related hypophysitis 
responded well to glucocorticoid therapy. Although 
methylprednisolone pulse therapy was used initially, 
oral prednisolone therapy is also effective. The initial 
dose of prednisolone is 0.6 mg/kg for 2–4 weeks, which 
is then tapered by 5 mg every 1–2 weeks for 2–3 months 
to determine a maintenance dose (2.5–5 mg/d). 
We gave our patient pulse therapy with a hope of 
recovering anterior and posterior pituitary functions as 
seen in other studies [14, 15]. However, in our patient 
at three months the endocrine axes did not recover.
Caputo et al. reported relapse in a case of IgG4-
related hypophysitis, after treatment with a high dose 
of prednisolone, who was then successfully treated with 
azathioprine [16]. 
Conclusions
IgG4-related diseases are rare and were recently rec-
ognised as a cause of hypophysitis. A high index of 
suspicion is required for clinching this rare diagnosis. 
Multiorgan involvement should lead to the consid-
eration of IgG4 diseases, which can be confirmed with 
serum IgG4 levels. Regular follow-up is important to 
pick up any new findings as early as possible.
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